| dc.creator | Kotsiou O.S., Karakousis N., Papagiannis D., Matsiatsiou E., Avgeri D., Fradelos E.C., Siachpazidou D.I., Perlepe G., Miziou A., Kyritsis A., Gogou E., Vavougios G.D., Kalantzis G., Gourgoulianis K.I. | en |
| dc.date.accessioned | 2023-01-31T08:44:50Z | |
| dc.date.available | 2023-01-31T08:44:50Z | |
| dc.date.issued | 2022 | |
| dc.identifier | 10.3390/jpm12111756 | |
| dc.identifier.issn | 20754426 | |
| dc.identifier.uri | http://hdl.handle.net/11615/75219 | |
| dc.description.abstract | Background: Both SARS-CoV-2 infection and/or vaccination result in the production of SARS-CoV-2 antibodies. We aimed to compare the antibody titers against SARS-CoV-2 in different scenarios for antibody production. Methods: A surveillance program was conducted in the municipality of Deskati in January 2022. Antibody titers were obtained from 145 participants while parallel recording their infection and/or vaccination history. The SARS-CoV-2 IgG II Quant method (Architect, Abbott, IL, USA) was used for antibody testing. Results: Advanced age (>56 years old) was associated with higher antibody titers. No significant differences were detected in antibody titers among genders, BMI, smoking status, comorbidities, vaccine brands, and months after the last dose. Hospitalization length and re-infection were predictors of antibody titers. The individuals who were fully or partially vaccinated and were also double infected had the highest antibody levels (25,017 ± 1500 AU/mL), followed by people who were fully vaccinated (20,647 ± 500 AU/mL) or/partially (15,808 ± 1800 AU/mL) vaccinated and were infected once. People who were only vaccinated had lower levels of antibodies (9946 ± 300 AU/mL), while the lowest levels among all groups were found in individuals who had only been infected (1124 ± 200 AU/mL). Conclusions: Every hit (infection or vaccination) gives an additional boost to immunization status. © 2022 by the authors. | en |
| dc.language.iso | en | en |
| dc.source | Journal of Personalized Medicine | en |
| dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85141710343&doi=10.3390%2fjpm12111756&partnerID=40&md5=024d34f329a2684c44048832b1b0b640 | |
| dc.subject | angiotensin converting enzyme 2 | en |
| dc.subject | cyclic GMP | en |
| dc.subject | cyclic GMP dependent protein kinase | en |
| dc.subject | iloprost | en |
| dc.subject | methemoglobin | en |
| dc.subject | nitric oxide | en |
| dc.subject | nose spray | en |
| dc.subject | oxyhemoglobin | en |
| dc.subject | prostacyclin | en |
| dc.subject | SARS-CoV-2 antibody | en |
| dc.subject | treprostinil | en |
| dc.subject | vasodilator agent | en |
| dc.subject | adult respiratory distress syndrome | en |
| dc.subject | airway pressure | en |
| dc.subject | apoptosis | en |
| dc.subject | Article | en |
| dc.subject | artificial ventilation | en |
| dc.subject | atelectasis | en |
| dc.subject | autopsy | en |
| dc.subject | bleeding time | en |
| dc.subject | breathing rate | en |
| dc.subject | bronchodilatation | en |
| dc.subject | coronavirus disease 2019 | en |
| dc.subject | Coronavirus infection | en |
| dc.subject | disease severity | en |
| dc.subject | dizziness | en |
| dc.subject | dyspnea | en |
| dc.subject | endothelium cell | en |
| dc.subject | extracorporeal oxygenation | en |
| dc.subject | fluid resuscitation | en |
| dc.subject | gas exchange | en |
| dc.subject | headache | en |
| dc.subject | heart failure | en |
| dc.subject | heart right ventricle failure | en |
| dc.subject | hospitalization | en |
| dc.subject | human | en |
| dc.subject | hypertension | en |
| dc.subject | hypotension | en |
| dc.subject | hypoxemia | en |
| dc.subject | hypoxia | en |
| dc.subject | intensive care unit | en |
| dc.subject | length of stay | en |
| dc.subject | lung artery pressure | en |
| dc.subject | lung blood vessel | en |
| dc.subject | lung compliance | en |
| dc.subject | lung parenchyma | en |
| dc.subject | lung vasoconstriction | en |
| dc.subject | lung ventilation | en |
| dc.subject | morbidity | en |
| dc.subject | mortality | en |
| dc.subject | muscle relaxation | en |
| dc.subject | nebulization | en |
| dc.subject | oxidative stress | en |
| dc.subject | oxygenation | en |
| dc.subject | pathophysiology | en |
| dc.subject | pneumonia | en |
| dc.subject | positive end expiratory pressure ventilation | en |
| dc.subject | pulmonary hypertension | en |
| dc.subject | respiratory distress | en |
| dc.subject | respiratory failure | en |
| dc.subject | resuscitation | en |
| dc.subject | sepsis | en |
| dc.subject | Severe acute respiratory syndrome coronavirus 2 | en |
| dc.subject | tachypnea | en |
| dc.subject | MDPI | en |
| dc.title | The Comparative Superiority of SARS-CoV-2 Antibody Response in Different Immunization Scenarios | en |
| dc.type | journalArticle | en |